200 related articles for article (PubMed ID: 24568617)
1. Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.
Wang K; Xu L; Yuan Z; Yao K; Zhao J; Xu L; Fang A; Zhang M; Wu L; Ji J; Hou J; Liu Q; Sun X
BMC Ophthalmol; 2014 Feb; 14():21. PubMed ID: 24568617
[TBL] [Abstract][Full Text] [Related]
2. Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting.
Park KH; Simonyi S; Kim CY; Sohn YH; Kook MS
BMC Ophthalmol; 2014 Dec; 14():160. PubMed ID: 25519810
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension.
Ling Z; Zhang M; Hu Y; Yin Z; Xing Y; Fang A; Ye J; Chen X; Liu D; Wang Y; Sun W; Dong Y; Sun X
Chin Med J (Engl); 2014; 127(5):905-10. PubMed ID: 24571886
[TBL] [Abstract][Full Text] [Related]
4. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.
DuBiner HB; Hubatsch DA
BMC Ophthalmol; 2014 Nov; 14():151. PubMed ID: 25432143
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study.
Kammer JA; Katzman B; Ackerman SL; Hollander DA
Br J Ophthalmol; 2010 Jan; 94(1):74-9. PubMed ID: 19726422
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study.
Feuerhake C; Buchholz P; Kimmich F
Curr Med Res Opin; 2009 Apr; 25(4):1037-43. PubMed ID: 19290780
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
Ozturk F; Ermis SS; Inan UU
Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
[TBL] [Abstract][Full Text] [Related]
9. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
Gandolfi SA; Cimino L
Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
[TBL] [Abstract][Full Text] [Related]
10. Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study.
Chen YY; Wang TH; Liu C; Wu KY; Chiu SL; Simonyi S; Lu DW
BMC Ophthalmol; 2016 Sep; 16(1):162. PubMed ID: 27633513
[TBL] [Abstract][Full Text] [Related]
11. Bimatoprost and bimatoprost/timolol fixed combination in patients with open-angle glaucoma and ocular hypertension.
Katsanos A; Dastiridou AI; Fanariotis M; Kotoula M; Tsironi EE
J Ocul Pharmacol Ther; 2011 Feb; 27(1):67-71. PubMed ID: 21214361
[TBL] [Abstract][Full Text] [Related]
12. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.
Parrish RK; Palmberg P; Sheu WP;
Am J Ophthalmol; 2003 May; 135(5):688-703. PubMed ID: 12719078
[TBL] [Abstract][Full Text] [Related]
13. Comparing bimatoprost and travoprost in black Americans.
Noecker RJ; Earl ML; Mundorf TK; Silverstein SM; Phillips MP
Curr Med Res Opin; 2006 Nov; 22(11):2175-80. PubMed ID: 17076978
[TBL] [Abstract][Full Text] [Related]
14. Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial.
Goldberg I; Gil Pina R; Lanzagorta-Aresti A; Schiffman RM; Liu C; Bejanian M
Br J Ophthalmol; 2014 Jul; 98(7):926-31. PubMed ID: 24667994
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study.
Casson RJ; Liu L; Graham SL; Morgan WH; Grigg JR; Galanopoulos A; Crawford A; House PH
J Glaucoma; 2009; 18(8):582-8. PubMed ID: 19826386
[TBL] [Abstract][Full Text] [Related]
16. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
Lin L; Zhao YJ; Chew PT; Sng CC; Wong HT; Yip LW; Wu TS; Bautista D; Teng M; Khoo AL; Lim BP
Ann Pharmacother; 2014 Dec; 48(12):1585-93. PubMed ID: 25184309
[TBL] [Abstract][Full Text] [Related]
19. Incidence of hyperemia associated with bimatoprost treatment in naïve subjects and in subjects previously treated with latanoprost.
Kurtz S; Mann O
Eur J Ophthalmol; 2009; 19(3):400-3. PubMed ID: 19396785
[TBL] [Abstract][Full Text] [Related]
20. Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study.
Nakano T; Mizoue S; Fuse N; Iwase A; Matsumoto S; Yoshikawa K
Adv Ther; 2015 Sep; 32(9):823-37. PubMed ID: 26424331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
